{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:11:21Z","timestamp":1773843081828,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Over 100,000 people are diagnosed with cutaneous melanoma each year in the United States. Despite recent advancements in metastatic melanoma treatment, such as immunotherapy, there are still over 7000 melanoma-related deaths each year. Melanoma is a highly heterogenous disease, and many underlying genetic drivers have been identified since the introduction of next-generation sequencing. Despite clinical staging guidelines, the prognosis of metastatic melanoma is variable and difficult to predict. Bioinformatic and machine learning analyses relying on genetic, clinical, and histopathologic inputs have been increasingly used to risk stratify melanoma patients with high accuracy. This literature review summarizes the key genetic drivers of melanoma and recent applications of bioinformatic and machine learning models in the risk stratification of melanoma patients. A robustly validated risk stratification tool can potentially guide the physician management of melanoma patients and ultimately improve patient outcomes.<\/jats:p>","DOI":"10.3390\/genes12111751","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:21:08Z","timestamp":1635805268000},"page":"1751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Emily","family":"Ma","sequence":"first","affiliation":[{"name":"Baltimore, MD 21230, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Hoegler","sequence":"additional","affiliation":[{"name":"Baltimore, MD 21230, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-9825","authenticated-orcid":false,"given":"Albert","family":"Zhou","sequence":"additional","affiliation":[{"name":"Baltimore, MD 21230, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"ref_1","unstructured":"(2021, July 11). Cancer Facts & Figures. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma (KEYNOTE-006): Post-Hoc 5-Year Results from an Open-Label, Multicentre, Randomised, Controlled, Phase 3 Study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000064535","article-title":"Photocarcinogenesis: UVA vs. UVB Radiation","volume":"15","year":"2002","journal-title":"Ski. Pharm. Appl Ski. Physiol."},{"key":"ref_5","first-page":"1005","article-title":"Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/308069a0","article-title":"Transforming Ras Genes from Human Melanoma: A Manifestation of Tumour Heterogeneity?","volume":"308","author":"Albino","year":"1984","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":"Germline P16 Mutations in Familial Melanoma","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/edm.09.2","article-title":"Genetics and Genomics of Melanoma","volume":"4","author":"Ghosh","year":"2009","journal-title":"Expert Rev. Derm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/v6010106","article-title":"Historical Perspective, Development and Applications of Next-Generation Sequencing in Plant Virology","volume":"6","author":"Barba","year":"2014","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A Landscape of Driver Mutations in Melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome Sequencing Identifies Recurrent Somatic RAC1 Mutations in Melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_15","unstructured":"(2021, August 21). The Cancer Genome Atlas Program\u2014National Cancer Institute, Available online: https:\/\/www.cancer.gov\/about-nci\/organization\/ccg\/research\/structural-genomics\/tcga."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-Genome Landscapes of Major Melanoma Subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fonc.2013.00184","article-title":"MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways","volume":"3","author":"Trevarton","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_18","first-page":"7","article-title":"Genomics of Cutaneous Melanoma: Focus on next-Generation Sequencing Approaches and Bioinformatics","volume":"3","author":"Papadodima","year":"2019","journal-title":"J. Transl. Genet. Genom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","article-title":"Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Resected High-Risk Stage III Melanoma in the United States","volume":"22","author":"Bensimon","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering Adjuvant Therapy for Stage II Melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome","volume":"16","author":"Busch","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene Expression Profiling for Molecular Staging of Cutaneous Melanoma in Patients Undergoing Sentinel Lymph Node Biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2020.0894","article-title":"Gene Expression Profile Testing for Thin Melanoma: Evidence to Support Clinical Use Remains Thin","volume":"156","author":"Kovarik","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zager, J.S., Gastman, B.R., Leachman, S., Gonzalez, R.C., Fleming, M.D., Ferris, L.K., Ho, J., Miller, A.R., Cook, R.W., and Covington, K.R. (2018). Performance of a Prognostic 31-Gene Expression Profile in an Independent Cohort of 523 Cutaneous Melanoma Patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4016-3"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of Patients at Risk of Metastasis Using a Prognostic 31-Gene Expression Profile in Subpopulations of Melanoma Patients with Favorable Outcomes by Standard Criteria","volume":"80","author":"Gastman","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","article-title":"Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-Analysis","volume":"156","author":"Marchetti","year":"2020","journal-title":"JAMA Derm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jamcollsurg.2020.08.750","article-title":"Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma","volume":"231","author":"Hu","year":"2020","journal-title":"J. Am. Coll. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1111\/jcmm.15822","article-title":"Screening and Identification of Potential Prognostic Biomarkers in Metastatic Skin Cutaneous Melanoma by Bioinformatics Analysis","volume":"24","author":"Sheng","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_36","first-page":"1132","article-title":"Identification of Hub Genes Associated With Melanoma Development by Comprehensive Bioinformatics Analysis","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cpt.1724","article-title":"A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated with Nivolumab Clearance in Patients with Advanced Melanoma","volume":"107","author":"Wang","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma MicroRNA Signature Predicts Post-Recurrence Survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e04811","DOI":"10.1016\/j.heliyon.2020.e04811","article-title":"Risk Prediction in Cutaneous Melanoma Patients from Their Clinico-Pathological Features: Superiority of Clinical Data over Gene Expression Data","volume":"6","author":"Arora","year":"2020","journal-title":"Heliyon"},{"key":"ref_40","first-page":"PO.19.00206","article-title":"Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2021.05.026","article-title":"Deep Learning Approach to Predict Sentinel Lymph Node Status Directly from Routine Histology of Primary Melanoma Tumours","volume":"154","author":"Brinker","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.18632\/oncotarget.2907","article-title":"Stage-Specific Prognostic Biomarkers in Melanoma","volume":"6","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1245\/s10434-020-09277-w","article-title":"Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma","volume":"28","author":"Farrow","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41467-021-21207-2","article-title":"Tumour Gene Expression Signature in Primary Melanoma Predicts Long-Term Outcomes","volume":"12","author":"Garg","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e6173206","DOI":"10.1155\/2021\/6173206","article-title":"M5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning","volume":"2021","author":"Huang","year":"2021","journal-title":"J. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1078-0432.CCR-20-2415","article-title":"Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma","volume":"27","author":"Johannet","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-Operative CtDNA Predicts Survival in High-Risk Stage III Cutaneous Melanoma Patients","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1878-0261.12732","article-title":"Serum Markers Improve Current Prediction of Metastasis Development in Early-Stage Melanoma Patients: A Machine Learning-Based Study","volume":"14","author":"Mancuso","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.18632\/oncotarget.6394","article-title":"Molecular Pathway Activation Features Linked with Transition from Normal Skin to Primary and Metastatic Melanomas in Human","volume":"7","author":"Shepelin","year":"2015","journal-title":"Oncotarget"},{"key":"ref_50","first-page":"2907","article-title":"A Multigene Support Vector Machine Predictor for Metastasis of Cutaneous Melanoma","volume":"17","author":"Wei","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1245\/ASO.2005.05.016","article-title":"A Nomogram That Predicts the Presence of Sentinel Node Metastasis in Melanoma With Better Discrimination Than the American Joint Committee on CancerStaging System","volume":"12","author":"Wong","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_52","first-page":"1178","article-title":"A Six-Long Non-Coding RNA Signature Predicts Prognosis in Melanoma Patients","volume":"52","author":"Yang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fonc.2019.01045","article-title":"Superpixel-Based Conditional Random Fields (SuperCRF): Incorporating Global and Local Context for Enhanced Deep Learning in Melanoma Histopathology","volume":"9","author":"Failmezger","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1245\/s10434-008-0077-x","article-title":"Validation of a Nomogram to Predict the Presence of Sentinel Lymph Node Metastases in Melanoma","volume":"15","author":"Canteras","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ejso.2011.05.007","article-title":"Maximizing the Clinical Usefulness of a Nomogram to Select Patients Candidate to Sentinel Node Biopsy for Cutaneous Melanoma","volume":"37","author":"Pasquali","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11845-014-1166-4","article-title":"Validation of a Nomogram Predicting Sentinel Lymph Node Status in Melanoma in an Irish Population","volume":"184","author":"Woods","year":"2015","journal-title":"Ir. J. Med. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tig.2017.12.005","article-title":"Supervised Machine Learning for Population Genetics: A New Paradigm","volume":"34","author":"Schrider","year":"2018","journal-title":"Trends Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3920","article-title":"Machine Learning Applications in Genetics and Genomics","volume":"16","author":"Libbrecht","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/09546634.2019.1682500","article-title":"Systematic Review of Machine Learning for Diagnosis and Prognosis in Dermatology","volume":"31","author":"Thomsen","year":"2020","journal-title":"J. Dermatol. Treat."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/11\/1751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:31Z","timestamp":1760167411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/11\/1751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["genes12111751"],"URL":"https:\/\/doi.org\/10.3390\/genes12111751","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]}}}